Biogen, which has a major manufacturing facility in Durham, saw its stock spike sharply Thursday after an abstract on results from a Phase I Prime study on its Alzheimer’s drug leaked.
The company, which has 1,300 employees at its Durham manufacturing and patient services operation, found that patients treated with a titrated dose of aducanumab had lower rates of brain swelling but maintained cognitive improvement. A titrated dose is adjusted by a doctor for each patient.
Titration dosing resulted in significant reductions in amyloid plaque burden during 12 months of treatment with less brain swelling than with fixed doses.
Biogen stock (Nasdaq:BIIB) closed at $289.54, up nearly 5 percent Thursday and gained an additional 4.9 percent in pre-market trading, rising to $303.73. It stands to gain billions in market capitalization from the gains. It’s current market cap is $63 billion.
